Generation, secretion and degradation of cancer immunotherapy target PD-L1

Autor: Dan-Dan Shen, Ya-Ping Bi, Jing-Ru Pang, Li-Juan Zhao, Long-Fei Zhao, Ya Gao, Bo Wang, Hui-Min Liu, Ying Liu, Ning Wang, Yi-Chao Zheng, Hong-Min Liu
Rok vydání: 2022
Předmět:
Zdroj: Cellular and Molecular Life Sciences. 79
ISSN: 1420-9071
1420-682X
DOI: 10.1007/s00018-022-04431-x
Popis: Cancer immunotherapy is a rapidly developing and effective method for the treatment of a variety of malignancies in recent years. As a significant immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) play the most significant role in cancer immune escape and cancer immunotherapy. Though PD-L1 have become an important target for drug development and there have been various approved drugs and clinic trials targeting it, and various clinical response rate and adverse reactions prevent many patients from benefiting from it. In recent years, combination trials have become the main direction of PD-1/PD-L1 antibodies development. Here, we summarized PD-L1 biofunctions and key roles in various cancers along with the development of PD-L1 inhibitors. The regulators that are involved in controlling PD-L1 expression including post-translational modification, mRNA level regulation as well as degradation and exosome secretory pathway of PD-L1 were focused. This systematic summary may provide comprehensive understanding of different regulations on PD-L1 as well as a broad prospect for the search of the important regulator of PD-L1. The regulatory factors of PD-L1 can be potential targets for immunotherapy and increase strategies of immunotherapy in combination.
Databáze: OpenAIRE
Externí odkaz: